About this item:

476 Views | 1,145 Downloads

Author Notes:

Address correspondence and reprint requests to E. Mignot, Sleep Research Center, Stanford University, 701 Welch Road, Suite 2226, Palo Alto, CA 94304.


Research Funding:

Supported by the National Institute of Neurological Diseases and Stroke (NS23724 and NS33797 to E. Mignot).


  • Science & Technology
  • Life Sciences & Biomedicine
  • Clinical Neurology
  • Neurosciences & Neurology
  • HLA-DR2

HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy


Journal Title:



Volume 48, Number 6


, Pages 1550-1556

Type of Work:

Article | Final Publisher PDF


Narcolepsy is considered a homogeneous clinical entity when excessive daytime sleepiness and cataplexy are present. Cataplexy is a polymerphic symptom that can be very mild and is thus subjectively defined. The Multiple Sleep Latency Test (MSLT) is widely used as a diagnostic test for narcolepsy. A short mean sleep latency and multiple sleep onset REM periods (SOREMPs) are typically observed in narcoleptic patients. The discovery of a tight association of narcolepsy with HLA class II antigens offers a unique opportunity to explore the respective value of the MSLT or of the presence of clear-cut cataplexy in defining an etiologically homogeneous group of narcoleptic patients. In this study, we carried out HLA typing for DR15(DR2) and DQB1*0602 in 188 narcoleptic patients with cataplexy in three ethnic groups (24 Asians, 61 Blacks, and 163 Caucasians). These results confirm the importance of DQB1*0602 typing rather than DR15 (DR2) typing in Black narcoleptic patients and demonstrate that the presence of clear-cut cataplexy is a better predictor for DQB1*0602 positivity than the presence of abnormal MSLT results.

Copyright information:

© 1997 by the American Academy of Neurology

Export to EndNote